Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · Real-Time Price · USD
1.110
+0.040 (3.74%)
At close: Aug 13, 2025, 4:00 PM
1.070
-0.040 (-3.60%)
Pre-market: Aug 14, 2025, 8:07 AM EDT
Enveric Biosciences Employees
As of December 31, 2024, Enveric Biosciences had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees decreased by 1 or -14.29% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-14.29%
Revenue / Employee
n/a
Profits / Employee
-$1,550,506
Market Cap
2.74M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | -1 | -14.29% |
| Dec 31, 2023 | 7 | -19 | -73.08% |
| Dec 31, 2022 | 26 | 2 | 8.33% |
| Dec 31, 2021 | 24 | 21 | 700.00% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ENVB News
- 1 hour ago - Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results - Business Wire
- 22 days ago - Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series - Business Wire
- 4 weeks ago - Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD) - Business Wire
- 7 weeks ago - Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003 - Business Wire
- 2 months ago - Enveric Biosciences Announces Participation in 2025 BIO International Convention - Business Wire
- 2 months ago - Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders - Business Wire
- 2 months ago - Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds - Business Wire
- 2 months ago - Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003 - Business Wire